8-K: Vivani Medical Advances GLP-1 Implant Programs, Reports Q2 2024 Financials

Vivani Medical announced progress in its GLP-1 implant programs, including the expected initiation of a first-in-human study for its obesity implant in Q4 2024, and reported its second quarter 2024 financial results.

Summary

• Vivani Medical reported its second quarter 2024 financial results and provided a business update, highlighting advancements in its GLP-1 implant programs.
• The company expects to initiate a first-in-human clinical study for its NPM-115 obesity implant in the fourth quarter of 2024.
• The FDA has cleared the Investigational New Drug Application for NPM-119, a six-month subdermal GLP-1 implant for type 2 diabetes.
• Vivani's cash balance was $26.3 million as of June 30, 2024, which is expected to support operations into the second half of 2025.
• The company's net loss for the second quarter of 2024 was $5.3 million, an improvement from the $6.5 million loss in the same period of 2023.
• Research and development expenses decreased by 9% to $3.5 million in Q2 2024, compared to $3.9 million in Q2 2023.
• General and administrative expenses decreased by 31% to $2.2 million in Q2 2024, compared to $3.1 million in Q2 2023.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the progress in clinical development, regulatory approvals, and improved financial metrics. The company is moving forward with its pipeline and has a clear path to clinical trials. However, the company is still operating at a loss and has risks associated with clinical development and regulatory approval.

Positives

• The company has made significant progress in advancing its GLP-1 implant programs.
• The FDA clearance of the IND for NPM-119 is a major milestone.
• The company has a solid financial position with cash to support operations into the second half of 2025.
• The company has reduced its operating expenses, leading to a smaller net loss compared to the same period last year.
• Preclinical data suggests the NPM-115 implant has comparable weight loss effects to semaglutide.
• The company's NanoPortal technology has the potential to improve medication adherence and tolerability.
• The company has a diversified pipeline with programs targeting obesity and type 2 diabetes.

Negatives

• The company is still operating at a loss, with a net loss of $5.3 million in Q2 2024.
• The company's cash balance decreased by $4.7 million in the second quarter of 2024.
• The company is dependent on third parties for manufacturing, research, and testing.
• The company has a history of losses and may need to raise additional capital in the future.
• The company's products are still investigational and have not been approved by any regulatory authority.

Risks

• The company faces risks related to the development and commercialization of its products, including NPM-115 and NPM-119.
• There are potential delays in the development of Vivani's products due to applicable laws, regulations, and guidelines.
• The company may face delays in submitting and receiving regulatory clearance or approval to conduct development activities.
• There are risks related to the initiation, enrollment, and conduct of planned clinical trials and the results therefrom.
• The company may not be able to access additional capital or otherwise fund its business.
• Market conditions and the ability of Cortigent to complete its initial public offering are also risks.
• The company is dependent on third parties for some or all aspects of its product manufacturing, research and preclinical and clinical testing.

Future Outlook

Vivani is focused on advancing its GLP-1 implant programs, with the initiation of the first-in-human study for NPM-115 expected in Q4 2024 and study results anticipated in 2025. The company also plans to participate in multiple industry and investor conferences.

Management Comments

• Adam Mendelsohn, Ph.D., CEO, stated that the company achieved significant progress in advancing its GLP-1 implants for obesity and chronic weight management.
• Dr. Mendelsohn added that the company is now on the cusp of transitioning to a clinical-stage development phase biotechnology company.
• Dr. Mendelsohn noted that the company's portfolio of miniature, ultra long-acting GLP-1 implants have the potential to address medication non-adherence and tolerability.

Industry Context

The announcement comes amid a growing interest in GLP-1 therapies for obesity and diabetes, with a focus on improving medication adherence. Vivani's implant technology aims to address the limitations of current treatments, such as daily or weekly injections, by providing a long-acting, subdermal delivery system.

Comparison to Industry Standards

• The document references the high discontinuation rates of GLP-1 therapies like Wegovy (64% within the first year, 76% by year two), highlighting a significant unmet need that Vivani's technology aims to address.
• The document mentions Intarcia's ITCA 650 (a 6-month exenatide implant) as a relevant value analog, noting its challenges with FDA approval due to safety concerns related to irregular drug release. Vivani's NanoPortal technology is positioned as a solution to these issues.
• The document cites market research indicating strong adoption potential for a miniature, 6-month exenatide implant, with 56% of patients responding likely or definitely to get an implant if FDA approved, prescriber recommended, and covered by insurance.
• The document notes that the GLP-1 market is estimated to reach $130B by 2030, with >$60B for Obesity/Chronic Weight Management and >$60B for Type 2 Diabetes, indicating a large potential market for Vivani's products.

Stakeholder Impact

• Shareholders: The progress in clinical development and regulatory approvals is positive for shareholders, but the company's ongoing losses and need for future capital raises are a concern.
• Employees: The company's progress and financial stability are positive for employees.
• Customers: The potential for improved medication adherence and tolerability is positive for patients.
• Suppliers: The company's financial stability is positive for suppliers.
• Creditors: The company's financial stability is positive for creditors.

Next Steps

• Vivani anticipates receiving approval from a Human Research Ethics Committee in Australia to support initiation of the first-in-human study for the NPM-115 obesity implant program during the fourth quarter of 2024.
• The company plans to participate in multiple industry and investor conferences, including the H.C. Wainwright conference in September 2024 and Maxim's Virtual Healthcare Summit in October 2024.
• The company expects to report results from the LIBERATE-1 study in 2025.

Key Dates

Keywords

GLP-1 implant, obesity, type 2 diabetes, exenatide, semaglutide, NanoPortal, clinical trial, medication adherence, biopharmaceutical, drug delivery